BullBD Old Apps Site
Home
Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

ORIONPHARM

All Eps Dividend Board Agm Q1 Q2 Q3

ORIONPHARM 18-Nov-2018

Trading of the shares of the Company will be allowed only in the Spot Market and Block transactions will also be settled as per Spot settlement cycle with cum benefit from 19.11.2018 to 20.11.2018. Trading of the shares of the Company will remain suspended on record date i.e., 22.11.2018.

ORIONPHARM 15-Nov-2018

(Q1 Un-audited): Consolidated EPS was Tk. 0.98 for July-September, 2018 as against Tk. 1.10 for July-September, 2017; Consolidated NOCFPS was Tk. 2.62 for July-September, 2018 as against Tk. 2.53 for July-September, 2017. Consolidated NAV per share (including revaluation surplus) was Tk. 73.65 as on September 30, 2018 and Tk. 72.05 as on September 30, 2017. Consolidated NAV per share (excluding revaluation surplus) was Tk. 65.35 as on September 30, 2018 and Tk. 63.62 as on September 30, 2017.

ORIONPHARM 11-Nov-2018

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 14, 2018 at 5:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2018.

ORIONPHARM 01-Nov-2018

There will be no price limit on the trading of the shares of the Company today (01.11.2018) following its corporate declaration.

ORIONPHARM 01-Nov-2018

The Board of Directors has recommended 15% cash dividend for the year ended on June 30, 2018. Date of AGM: 10.12.2018, Time: 11:00 AM, Venue: Officer's Club, 26, Baily Road, Ramna, Dhaka. Record Date: 22.11.2018. The Company has also reported Consolidated EPS of Tk. 3.43, Consolidated NAV per share (including Revaluation Surplus) of Tk. 72.88 and Consolidated NOCFPS of Tk. 9.38 for the year ended on June 30, 2018 as against Tk. 3.40, Tk. 70.95 and Tk. 9.62 respectively for the year ended on June 30, 2017.

ORIONPHARM 24-Oct-2018

As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 31, 2018 at 5:00 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2018.

ORIONPHARM 15-Jul-2018

Credit Rating Agency of Bangladesh Limited (CRAB) has announced the Entity rating (Surveillance) of the Company as "A1" along with a stable outlook based on un-audited financial statements as of March 31, 2018, audited financial statement of the Company up to June 30, 2017; bank liability position as of April 30, 2018 and other relevant quantitative as well as qualitative information up to the date of rating declaration.

ORIONPHARM 30-Apr-2018

(Q3 Un-audited): Consolidated EPS was Tk. 0.69 for January-March 2018 as against Tk. 0.56 for Jan.-Mar. 2017; Consolidated EPS was Tk. 2.76 for July'17-March'18 as against Tk. 3.02 for July'16-March'17. Consolidated NOCFPS was Tk. 8.57 for July'17-March'18 as against Tk. 8.54 for July'16-March'17. Consolidated NAV per share (including and excluding Revaluation Surplus) was Tk. 72.07 and Tk. 63.71 respectively as on March 31, 2018 as against Tk. 70.95 and Tk. 62.48 respectively as on June 30, 2017.

ORIONPHARM 23-Apr-2018

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 28, 2018 at 5:30 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended on March 31, 2018.

ORIONPHARM 29-Jan-2018

(Continuation news of ORIONPHARM): Consolidated NAV per share Including revaluation surplus was Tk. 71.46 as on December 31, 2017 and Tk. 70.95 as on June 30, 2017. Consolidated NAV per share Excluding revaluation surplus was Tk. 63.06 as on December 31, 2017 and Tk. 62.48 as on June 30, 2017. (end)

Previous Next page